PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
Top Cited Papers
Open Access
- 13 July 2017
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 130 (2), 221-228
- https://doi.org/10.1182/blood-2017-01-761346
Abstract
Key Points: Checkpoint blockade via anti–PD-1 mAbs was associated with a high overall response rate in relapsed Hodgkin lymphoma allo-HCT patients. Checkpoint blockade via anti–PD-1 mAbs after allo-HCT can be complicated by rapid onset of severe and treatment-refractory GVHD.Keywords
This publication has 64 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Advances in graft-versus-host disease biology and therapyNature Reviews Immunology, 2012
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaBlood, 2011
- PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cellsBlood, 2011
- Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in miceJournal of Clinical Investigation, 2010
- Acute graft-versus-host disease: from the bench to the bedsideBlood, 2009
- B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disordersBlood, 2009
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantationBlood, 2009
- Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin LymphomaTransplantation and Cellular Therapy, 2008